Literature DB >> 19845790

Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up.

Jeremy St J Thomas1, Gillian R Kerr, Wilma J L Jack, Fiona Campbell, Laura McKay, Hans-Christian Pedersen, Ian H Kunkler, David A Cameron, Udi Chetty, John M S Bartlett.   

Abstract

AIMS: To assess the validity of grading in the Edinburgh Breast Conservation Series; a consecutive cohort of 1812 early breast cancer patients treated by breast conservation and radiotherapy between 1981 and 1998 in a single specialist centre with > or =9 years' follow-up and full staging data. METHODS AND
RESULTS: A single pathologist (J.St.J.T) graded 1650 cases using the Elston and Ellis method (EE) with particular reference to the component data: acinar differentiation, nuclear pleomorphism and mitotic counts. The original method was then compared with binary scoring of the same components and the relationship to prognosis reassessed. EE grades and individual grade components were prognostic (P < 0.0001) with 10-year cause-specific survival of 95.6%, 86.4% and 74.7% for EE grades 1, 2 and 3, respectively. A binary scoring of grade components produces four groups, splitting EE grade 2 tumours into two groups with different outcomes--10-year survival rates for the four revised grades were 96.0%, 89.0%, 79.7% and 75.4%, respectively.
CONCLUSIONS: Existing grading methodology is fully applicable in the narrower context of a conservation series but can be simplified. Subdivision of EE grade 2 into a true intermediate prognosis group and a second group with a worse prognosis also adds benefit.

Entities:  

Mesh:

Year:  2009        PMID: 19845790     DOI: 10.1111/j.1365-2559.2009.03429.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

1.  FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Christos Colovos; Kei Suzuki; Nabil P Rizk; Mark P S Dunphy; Emily C Zabor; Camelia S Sima; Akihiko Yoshizawa; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

2.  A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Authors:  Kyuichi Kadota; Kei Suzuki; Christos Colovos; Camelia S Sima; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Mod Pathol       Date:  2011-10-07       Impact factor: 7.842

3.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2012-04-13       Impact factor: 7.842

4.  Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Kaitlin M Woo; Camelia S Sima; David J Finley; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

5.  The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Camelia S Sima; Valerie W Rusch; Andre L Moreira; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2013-11-01       Impact factor: 7.842

6.  Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk.

Authors:  Solange Torchia Carvalho; Monica Maria Stiepcich; José Humberto Fregnani; Sueli Nonogaki; Rafael Rocha; Fernando Augusto Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 7.  Breast cancer prognostic classification in the molecular era: the role of histological grade.

Authors:  Emad A Rakha; Jorge S Reis-Filho; Frederick Baehner; David J Dabbs; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Andrea L Richardson; Stuart J Schnitt; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Sunil Badve; Ian O Ellis
Journal:  Breast Cancer Res       Date:  2010-07-30       Impact factor: 6.466

8.  Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Authors:  John M S Bartlett; Jeremy Thomas; Douglas T Ross; Robert S Seitz; Brian Z Ring; Rodney A Beck; Hans Christian Pedersen; Alison Munro; Ian H Kunkler; Fiona M Campbell; Wilma Jack; Gillian R Kerr; Laura Johnstone; David A Cameron; Udi Chetty
Journal:  Breast Cancer Res       Date:  2010-07-08       Impact factor: 6.466

9.  FKBPL: a marker of good prognosis in breast cancer.

Authors:  Laura Nelson; Hayley D McKeen; Andrea Marshall; Laoighse Mulrane; Jane Starczynski; Sarah J Storr; Fiona Lanigan; Christopher Byrne; Ken Arthur; Shauna Hegarty; Ahlam Abdunnabi Ali; Fiona Furlong; Helen O McCarthy; Ian O Ellis; Andrew R Green; Emad Rakha; Leonie Young; Ian Kunkler; Jeremy Thomas; Wilma Jack; David Cameron; Karin Jirström; Anita Yakkundi; Lana McClements; Stewart G Martin; William M Gallagher; Janet Dunn; John Bartlett; Darran O'Connor; Tracy Robson
Journal:  Oncotarget       Date:  2015-05-20

10.  Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.

Authors:  J Stephen; G Murray; D A Cameron; J Thomas; I H Kunkler; W Jack; G R Kerr; T Piper; C L Brookes; D W Rea; C J H van de Velde; A Hasenburg; C Markopoulos; L Dirix; C Seynaeve; J M S Bartlett
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.